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Abstract
Background: To define different prognostic groups of surgical colorectal adenocarcinoma patients derived from
recursive partitioning analysis (RPA).
Methods: Ten thousand four hundred ninety four patients with colorectal adenocarcinoma underwent colorectal
resection from Taiwan Cancer Database during 2003 to 2005 were included in this study. Exclusion criteria included
those patients with stage IV disease or without number information of lymph nodes. For the definition of risk
groups, the method of classification and regression tree was performed. Main primary outcome was 5-year cancer-
specific survival.
Results: We identified six prognostic factors for cancer-specific survival, resulting in seven terminal nodes. Four risk
groups were defined as following: Group 1 (mild risk, 1,698 patients), Group 2 (moderate risk, 3,129 patients), Group
3 (high risk, 4,605 patients) and Group 4 (very high risk, 1,062 patients). The 5-year cancer-specific survival for Group
1, 2, 3, and 4 was 86.6%, 62.7%, 55.9%, and 36.6%, respectively (p < 0.001). Hazard ratio of death was 2.13, 5.52 and
10.56 (95% confidence interval 1.74-2.60, 4.58-6.66 and 8.66-12.9, respectively) times for Group 2, 3, and 4 as
compared to Group 1. The predictive capability of these grouping was also similar in terms of overall and
progression-free survival.
Conclusion: The use of RPA offered an alternative grouping method that could predict the survival of patients
who underwent surgery for colorectal adenocarcinoma.
Keywords: Recursive Partitioning Analysis, Colorectal Cancer, Survival Analysis
Background
Adenocarinoma is the most commonly seen malignancy
of colon and rectum, which ranks the third leading cause
for cancer death both in USA and Taiwan as well as the
fourth cause worldwide [1]. Although the diagnostic
instrument and treatment modality had made a huge
progress leap in recent decade, the survival outcome of
colorectal cancer patients didn’t keep up the identical or
similar pace by multiple factors [2]. Clinical practice
guideline and performance measurement came up with
the impetus to formalize clinicians’ d a i l yp r a c t i c ea n d
possibly improve patients’ survival thereafter. The most
frequently accepted prognostic factor is TNM staging
system, but for real world, there are many factors beyond
TNM staging that can confound the patients’ survival.
Hence a risk group study may hopefully yield substantial
information that is succinct and easily understood by
researchers, providers, practitioners, patients, and even
the policy makers to make appropriate choices.
Recursive partitioning analysis (RPA), a method of clas-
sification, was initially described by the Radiation Therapy
Oncology Group and was intended to provide a way that
divide patients into homogenous groups based on the
length of survival [3]. Advantages of this method include
not only making fewer modeling assumptions, but also
establishing procedure that adapts to missing values
through the use of surrogate measures [4]. Currently,
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sible for these tedious computations.
In this study, the main objective was to assign different
prognostic groups with regard to cancer-specific survival
derived from RPA among patients with newly diagnosed
colorectal adenocarcinoma who underwent colorectal
resection for cancer surgery from a population-based data.
We also compared these groups regarding three different
types of survival (overall survival, progression-free survival
and cancer-specific survival)
Methods
Study population
This study consisted of a consecutive series of 15,731
patients who were newly diagnosed with colorectal cancer
during the period of January 2003 to December 2005 from
a population-based database, Taiwan Cancer Database,
and linkage with TCDB to 2003-2009 Death Registries.
Taiwan Cancer Database (TCDB) was a nationwide pro-
gram that accounted for about 60% of patients with six
cancer types (breast, colon, liver, lung, cervical and buccal
cancer) per year and served as a good source for academic
research [1]. We identified colorectal cancer patients
newly registered into the TCDB according to ICD-O-3
(International Classification of Diseases for Oncology,
third revision) code C18.0 (cecum)-C21.8 (rectum). Exclu-
sion criteria included patients with stage IV, cancer at
anus, pathologic report beyond adenocarcinoma, without
colorectal resection, and unknown specification of cancer
stage as well as unavailability of lymph node information.
We also excluded patients whose survival status cannot be
verified as of December 31, 2009. This study was approved
by the institutional review board (IRB) at College of Public
Health, National Taiwan University.
Study outcomes
The primary end point was 5-year survival including over-
all survival, progression-free survival and disease-specific
survival. Overall survival rate denoted the percentage of
patients who were still alive for a certain period of time
after surgery for colorectal cancer. Progression-free survi-
val rate denoted the percentage of patients who were still
without any signs of colorectal cancer for a certain period
of time after surgery for colorectal cancer. Cancer-specific
survival rate (or disease-specific survival) referred to the
percentage of patients who had not died from colorectal
cancer or metastasis for a certain period of time after sur-
gery for colorectal cancer. All survival rates were calcu-
lated from the day of surgery (colorectal resection).
Statistical analysis
We used classification and regression (CRT) method,
developed for binominal data, in the analysis of RPA [5].
This technique is a nonparametric methodology that
creates a decision tree with respect to prognostic factors
and their interactions which are most important in deter-
mining the outcome. A parent node would split into
child nodes that are as homogenous as possible to depen-
dent variables. The split also followed the rules that the
corresponding cut-off points with the minimal P value,
provided the minimal P value was < = 0.0001 and that
the number of patients within the child node was at least
50. Then a tree-based model composed of nodes was
fashioned by recursively partitioning the study cohort.
During the RPA process of this study, a set of variables
had been evaluated as prognostic factors, including: age
(split at 50, 60, 70 years), gender (male vs. female),
comorbidity (Deyo’s modified version of the Charlson
comorbidity index - CCI) [6], tumor location (colon, sig-
moid, rectum), number of lymph nodes retrieved and
examined (continuous), distance of surgical margin to
tumor (positive or < 0.2 cm, 0.2 cm to 1 cm, > 1 cm),
depth of tumor invasion (submucosa, muscularis propria,
into subserosa, invasion to other organs), pathological
tumor size (0-2 cm, 2-3 cm, 3-4 cm, 4-6 cm, > 6 cm), his-
topathology (adenocarcinoma vs. mucinous adenocarci-
noma or signet ring cell adenocarcinoma), TNM stages
(stage I, stage II, stage III, based on the classification of
sixth edition of American Joint Commission on Cancer
Staging Manual), fluorouracil-based chemotherapy (yes
vs. no), radiotherapy (yes vs. no). Because CRT did not
stop in the middle of the tree-growing process, we
pruned tree to avoid overfitting by setting maximum dif-
ference in risk as 1. Also for validation, we randomly
assigned 50% cohort as training sample (for model build-
ing) and other 50% as test sample (for model validation).
After CRT algorithm, several terminal nodes were cre-
ated and these nodes would be combined into a group
when the significance level of comparison between two
terminal nodes was > 0.05. With these RPA group, we
used paired t-test to determine whether the 5-year overall,
5-year progression-free and 5-year disease-specific survival
differed significantly between these RPA groups. The
Kaplan-Meier method was used to calculate cumulative
survival. Differences in cumulative survival between two
groups were tested by the log-rank test. All P values were
two sided and a P < 0.05 was considered statistically signif-
icant. We used PASW Statistics 18 as statistic software for
all of the analyses reported in this study.
Results
Of 15,731 newly diagnosed colorectal cancer patients,
there were 12,860 patients who had undergone colorectal
resection for colorectal cancer (Figure 1). Among them,
2,126 patients (16.7%), 4,008 patients (31.5%), 4,383
patients (34.4%) and 2,227 patients (17.5%) presented
with stage I, stage II, stage III and stage IV disease,
respectively. We excluded 2,227 patients with stage IV
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Page 2 of 10disease, 116 patients with pathological report other than
adenocarcinoma or unavailable of lymph node counts,
and 23 patients whose survival status could not be veri-
fied. The resulting cohort, 10,494 patients, who under-
went colorectal resection in thirty-two major hospitals or
cancer centers were eligible to enter into this survival
tree analysis. The majority of patients were older than 70
years of age (39.8%, 4,173/10,494) and comorbidity
indexes were > = 3 (52.5%, 5,509/10,494) (Table 1).
Among these patients, male patients were slightly more
Excluded 23 patients whose 
survival status cannot be verified 
10,494 patients with non-stage IV colorectal   
adenocarcinoma underwent colorectal 
    resection  for  colorectal  cancer         
12,860 colorectal cancer patients 
   underwent  colorectal  resection 
Excluded 2,871 patients without 
undergoing colorectal resection 
Excluded 2,227 stage IV 
pathologic staging patients   
Excluded 116 patients with reports
other than adenocarcinoma or 
unavailable of lymph node counts 
10,633 patients with non-stage IV colorectal 
diseases underwent colorectal resection 
15,731 patients
Newly diagnosed colorectal cancer patients 
treated at 32 hospitals. (TCDB 2003, 2004, 2005)
10,517 surgical patients with non-stage 
IV colorectal adenocarcinoma 
Survival tree analysis
Figure 1 Schema of patients’enrollment in this study. (TCDB: Taiwan Cancer Database).
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N Cumulative survival (%) not died of cancer at
5-years
HR 95.0%
CI
Significance*
Gender 0.000
male 5,937 69% 1.00
female 4,557 73% 0.86 0.80-0.93
AGE 0.000
> 50 yrs, < = 60 yrs 1,994 76% 1.00
< 50 yrs 1,516 75% 1.19 1.03-1.38
> 60 yrs, < = 70 yrs 2,811 73% 1.14 1.01-1.30
> 70 yrs 4,173 64% 1.64 1.46-1.84
Co-morbidity (CCI) 0.000
CCI = 0+1 952 87% 1.00
CCI = 2 4,033 78% 1.51 1.24-1.85
CCI > = 3 5,509 62% 1.92 1.58-2.33
Tumor location 0.000
rectum 3,967 70% 1.00
sigmoid colon 3,115 72% 0.84 0.77-0.93
colon (except sigmoid colon) 3,230 70% 1.02 0.93-1.13
overlapping or unspecified 182 61% 1.17 0.90-1.53
Number of lymph node examined 0.013
< 12 3,850 70% 1.00
> = 12 6,644 72% 0.91 0.84-0.98
Surgical margin 0.000
< = 2 mm 657 57% 1.00
> 2 mm, < = 1 cm 3,382 69% 0.57 0.49-0.66
> 1 cm 5,816 75% 0.47 0.41-0.54
Depth of tumor invasion 0.000
submucosa 958 89% 1.00
muscularis propria 1,613 82% 1.26 0.73-2.18
through the muscularis propria into the
subserosa
6,315 68% 1.77 1.06-2.95
directly invades other organs or structures 1,608 58% 2.76 1.62-4.70
Tumor size 0.001
0-2 cm 625 79% 1.00
> 2.0, < = 3 cm 1,323 75% 0.82 0.66-1.02
> 3.0, < = 4 cm 2,067 72% 0.81 0.66-1.00
> 4.0, < = 6 cm 3,889 69% 0.82 0.67-1.01
> 6.0 cm 2,590 66% 0.98 0.80-1.21
Pathology
adenocarcinoma 10,016 71.6% 1.00 0.000
mucinous or signet ring cell adenocarcinoma 478 62.9% 1.50 1.27-1.76
TNM stage 0.000
stage I 2,114 88% 1.00
stage II 4,002 76% 1.23 0.96-1.58
stage III 4,378 56% 3.05 2.39-3.89
Radiotherapy 0.004
no 9,367 71% 1.00
yes 1,127 67% 1.21 1.07-1.38
Chemotherapy 0.000
no 5,385 68% 1.00
yes 5,109 73% 0.67 0.62-0.73
N: number; HR: hazard ratio; CI: confidence interval; CCI: Charlson comorbidity index; classification of TNM stage based on AJCC edition 6; *: log-rank P value
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Page 4 of 10than female patients (56.6%, 5,937/10,494). Rectum was
found to be the more frequent site of tumor location.
About 63.3% (6,644/10,494) patients had no less than
twelve lymph nodes examined and 59.0% (5,816/9,855) of
pathology reports proved that surgical margin was free of
tumor for more than 1 cm microscopically. In terms of
involvement depth and tumor size, most patients (60.2%,
6,315/10,494) had cancer penetrated through the muscu-
laris propria of colorectal wall into the subserosa and
tumors grew larger than 4 cm (61.7%, 6,479/10,494). Var-
iants of adenocarcinoma (such as mucinous adenocarci-
noma or signet ring cell adenocarcinoma, etc.) occurred
in only about 4.6% (478/10,494) of resected specimens.
Stage III comprised of 41.7% (4,378/10,494) patients, fol-
lowed by stage II which comprised of 38.1% (4,002/
10,494) patients. Nearly half patients received che-
motherapy 48.7% (5,109/10,494). However, much less
patient underwent radiotherapy [10.7% (1,127/10,494)].
The duration of follow-up time was 0- 84 months with a
mean of 48.9 months. P value of log-rank test for all fac-
tors was less than 0.01 (except number of lymph node
examined, P = 0.013) when 5-year cancer-specific survi-
val was designated as dependent variable. Paradoxically,
the hazard ratio of radiotherapy vs. no radiotherapy was
1.21.
We started the RPA with training sample of 5310
patients with 1,296 patients (24.4%) died in the study per-
iod. Tumor staging (TNM system) was the most impor-
tant factor that yielded a segment of 3,142 patients (16.0%
dead) with stage I & II disease and a segment of 2,168
patients (36.5% dead) with stage III disease (p < 0.001).
The same procedure continued following this splitting
algorithm (Figure 2). In the left segment, patient’sa g e
appeared to be the strongest factor (p < 0.001), which
yielded a subgroup of 2,465 patients with age < 76.1 years
(12.5% dead) and a subgroup of 677 patients with age ≥
76.1 years (28.7% dead) (p = 0.001). No further split was
possible in the node of stage I & II disease and age ≥ 76.1
years due to minimal criteria. The node with stage I & II
disease and age < 76.1 years could be split into a subgroup
of 849 patients with stage I disease (6.8% dead) and a sub-
group of 1,616 patients stage II disease (15.5% dead) (p <
0.001). No further split was possible in the node of stage I
disease and age < 76.1 years due to minimal criteria. But
we could split the node with stage II disease and age <
76.1 years into a subgroup of 153 patients who had num-
ber of lymph nodes examined < 6 (32.7% dead) and a sub-
group of 1,463 patients who had number of lymph nodes
examined ≥ 6 (13.7% dead), both of which were terminal
nodes.
In the right segment, comorbidity score (CCI) seemed
to be the strongest factor, by which yielded a subgroup of
166 patients with CCI < 2 (18.1% dead) and a subgroup
of 2002 patients with CCI ≥ 2 (38.1% alive) (p = 0.001).
T h en o d et h a tp a t i e n t sw i t hs t a g eI I Ia n dC C I<2w a sa
terminal node since no further split was possible. The
node that patient with stage III and CCI ≥ 2 could be
further split into a subgroup of 533 patients who didn’t
have chemotherapy treatment (50.1% dead) and a sub-
group of 1,469 patients who ever have been treated with
chemotherapy treatment (33.7% dead), both of which
were terminal nodes. The results of the RPA process
were validated with a test sample of 5,184 patients with
colorectal cancer which were independent of the model
building training sample (Figure 3). Both results were
closely correlated.
All Patients =5310 
75.6 % 
Stage I & II =3142
84.0 % 
Stage III =2168
63.5 % 
Age (<76.1 yrs) =2465 
87.5 % 
Age (>76.1 yrs) =677
71.3 % 
CCI (<2) =166
81.9 % 
CCI (>2) =2002
61.9 % 
Stage I =849 
93.2 % 
Stage II =1616
84.5 % 
No chemotherapy =533
49.9 % 
Chemotherapy =1469 
66.3 % 
LN (>6) =1463
86.3 % 
LN (<6) =153 
67.3 % 
Figure 2 Decision tree constructed by recursive partitioning analysis (training sample).
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Page 5 of 10Thus five prognostic factors were identified (namely,
TNM staging, age, comorbidity, number of lymph nodes
examined, chemotherapy) for cancer-specific survival,
resulting in seven terminal nodes. Based on mean survival
time of the terminal nodes, we were able to categorized
four risk groups (Table 2). Group 1 (mild risk) consisted
of 1,698 patients who had stage I colorectal cancer and
age < 76.1 years (119 deaths in the study period). Group 2
(moderate risk) consisted of 3,129 patients who had stage
II colorectal cancer, age < 76.1 years and number of lymph
nodes examined ≥ 6, or stage III colorectal cancer with
CCI < 2 (449 deaths in the study period). Group 3 (high
risk) consisted of 4,605 patients who had stage I&II color-
ectal cancer and age ≥ 76.1 years or stage II colorectal can-
cer, age < 76.1 years and number of lymph nodes
examination < 6, or stage III colorectal cancer CCI ≥ 2
with chemotherapy (1,502 deaths in the study period).
Group 4 (very high risk) consisted of 1,062 patients who
had stage III colorectal cancer, CCI ≥ 2 and without che-
motherapy (525 deaths in the study period).
Cancer-specific survival analysis using Kaplan-Meier
plot and log-rank test revealed significant differences
among groups (p < 0.0001, Figure 4). In addition, we also
utilized this RPA grouping classification to test the effects
on predicting overall and progression-free survivals (3-
year and 5-year respectively). Results showed good discri-
minating capability for this grouping classification to easily
predict each outcome for all endpoints (Table 3).
Discussion
This study explored the risk group definition of patients
with colorectal adenocarcinoma after surgery by CRT
algorithm. Risk group definition by RPA algorithm has
been already proposed to predict outcomes of several
benign and malignant diseases [3-5], but it was still rare
for colorectal cancer as well as other gastrointestinal
malignancy. For patients with rectal adenocarcinoma,
Zolbec et al. ever used this technique to identify a predic-
tive model with regard to patients’ responses to preopera-
tive radiotherapy from several molecular factors [7]. An
All Patients =5184 
74.9 % 
Stage I & II =2974
84.0 % 
Stage III =2210
62.6 % 
Age (<76.1 yrs) =2310 
87.3 % 
Age (>76.1 yrs) =664
72.8 % 
CCI (<2) =199
81.8 % 
CCI (>2) =2011
60.7 % 
Stage I =849 
92.8 % 
Stage II =1461
84.1 % 
No chemotherapy =529
51.0 % 
Chemotherapy =1482 
64.2 % 
LN (>6) =1300
86.1 % 
LN (<6) =161 
67.7 % 
Figure 3 Decision tree constructed by recursive partitioning analysis (test sample). The plots of recursive partitioning analysis (Figure 2
and Figure 3) were obtained from 10,494 patients who were documented to have adenocarcinoma from colon and rectum (anus was not
included) and underwent colorectal resection for cancer. (CCI: Charlson comorbidity index; LN: number of lymph nodes; yrs: years; the number in
the upper half of box indicated number of patients; the percentage in the upper half of box indicated cancer-specific survival percentage).
Table 2 Assignment of Recursive Partitioning Analysis (RPA) Groups
RPA class Definition (s) Patients Events
Group 1 (mild risk) stage I colorectal cancer and age < 76.1 years, 1,698 119
Group 2 (moderate risk) stage II colorectal cancer, age < 76.1 years and LN examined > = 6
stage III colorectal cancer, CCI < 2
3,129 449
Group 3 (high risk) stage I & II colorectal cancer, age ≥ 76.1 years
stage II colorectal cancer, age < 76.1 years and LN examined < 6
stage III colorectal cancer, CCI > = 2, with chemotherapy
4,605 1,502
Group 4 (very high risk) stage III colorectal cancer, CCI > = 2, without chemotherapy 1,062 525
RPA: recursive partitioning analysis; CCI: Charlson comorbidity index; LN: lymph node
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Page 6 of 10Figure 4 Survival analysis (cancer-specific survival as outcome) with Kaplan-Meier plot shows significant difference between groups (p
< 0.0001). (No.: number).
Table 3 The RPA groups and survival
RPA Group
Group 1 Group 2 Group 3 Group 4 P value
Overall survival
3-yrs (%) 91.5 84.1 65.7 45.2 < 0.001
5-yrs (%) 85.6 78.3 54.8 35.1 < 0.001
HR 1.00 1.70 4.12 7.88
95% CI 1.44-1.99 3.56-4.78 6.71-9.25
Progression-free survival
3-yrs (%) 94.2 86.0 69.4 51.7 < 0.001
5-yrs (%) 90.4 81.4 60.6 41.7 < 0.001
HR 1.00 2.25 5.42 9.91
95% CI 1.85-2.74 4.52-6.51 8.16-12.11
Cancer-specific survival
3-yrs (%) 94.5 87.5 70.5 52.1 < 0.001
5-yrs (%) 91.1 83.2 61.9 43.2 < 0.001
HR 1.00 2.13 5.52 10.56
95% CI 1.74-2.60 4.58-6.66 8.66-12.90
RPA: recursive partitioning analysis; yrs: years; HR: hazard ratio; CI: confidence interval
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credibly allows important clinical implication for
patients, surgeons and stakeholders to make appropriate
treatment decisions. In this study, the results yielded five
prognostic factors, which could be further used to define
four risk groups. These four RPA groups not only dif-
fered significantly with regard to cancer-specific survival
b u ta l s op r o v i d e dp r o g n o s t i c significance concerning
with progression-free survival as well as overall survival.
Traditionally, a prognostic or risk factor can be easily
identified through univariate or multivariate analyses from
Cox proportional hazards model as Table 1 demonstrated
in this study. It may be possible to predict a survival prob-
ability of a certain prognostic factor through Cox propor-
tional hazards model, however, it is always difficult to
interpret or predict a patient’s cumulative risk for a given
set of prognostic factors. In actual daily practice, patients
usually present with a lot of prognostic or risk factors,
especially when there are interaction terms involved.
Hence, provision a useful and informative risk group defi-
nition for empirical use is a tough task. Furthermore, the
cut-off values of defining risk groups in the hazard model
often are arbitrary [5]. Theoretically, multivariate regres-
sion model offers hazard ratio for entire population while
RPA allows different prognostic factors for different
branch of the tree model. Therefore, RPA is a better statis-
tic methodology when there are interactions between
prognostic (or risk) factors.
Several studies have documented the association
between patient attribute, tumor characteristics, process
(treatment), pathological finding and the survival of color-
ectal cancer. Prognostic or risk factors frequently observed
for survival are gender [8,9], age [9], comorbidity [10],
number of lymph nodes examined [11-13], tumor size
[14], tumor TNM staging [12,15], depth of tumor invasion
[16], safety surgical margin [17], chemotherapy [18-21]
and radiotherapy [22]. Except radiotherapy, the prognostic
significance of these variables was confirmed in our study
by Cox proportional hazard model. However, the impact
of predictability of radiotherapy with regard to cancer-spe-
cific survival in the hazard model, estimated through all
colorectal cohort (not stage III rectal cancer only), may
decreased even in the opposite direction as described in
the Method section.
Tumor stage was still the most important prognosticator
throughout this tree-structured model for cancer-specific
survival of patients with colorectal cancer. Patients with
stage III disease survived much shorter than patient with
stage I or II disease. For those patients with negative
lymph node status (stage I & II disease) in the left segment
of Figure 2, we identified that age as well as number of
lymph nodes examined were associated with patients’
long-term survival. For those patients with positive lymph
node status (stage III disease only) in the right segment,
we identified comorbidity index and chemotherapy were
associated with patients’ long-term survival. In other
words, age was a prognostic factor for patient with stage I
disease; while age and harvest lymph nodes ≥ 6 might pre-
dict long-term survival for patient with stage II disease.
Comorbidity index and chemotherapy were the most
important prognostic factors for patient with stage III dis-
ease. We noted in the subset of patients with stage III dis-
ease and CCI ≥ 2, chemotherapy had been identified as
one of the most important prognostic factors postopera-
tively for survival after colorectal surgery. The benefit was
about 15% improvement in survival. Compared to prior
report, Mamounas et al. had found chemotherapy resulted
in an increase of 18% survival in overall survival for stage
III colon cancers [23]. In a meta-analysis investigating the
usage of chemotherapy, Benson et al. had discovered the
14% decrease in 5-year mortality rate for stage II colon
cancer patients who received 5-FU based chemotherapy
[24]. However, our data failed to prove this advantage for
patient with stage II disease.
No matter where the tumor located (colon or rectum),
comorbidity exhibited an important predictive value for
long-term survival. Our results echoed the study of Kla-
bunde et al., who had demonstrated that comorbidity sta-
tus can predict long-term survival of patients with four
types of malignancy including colorectal cancer [10]. Ori-
ginally developed by epidemiologists to predict hospital
mortality of breast cancer, comorbidity seems to be useful
in predicting patient’s long-term survival with regard to
coexisting medical conditions and malignancies. Our
results also elucidated the importance of lymph node har-
vest of surgery for colorectal cancer, which was recently
endorsed or adopted by several academic societies and
healthcare management organizations to be a quality
metric for colorectal cancer care [25]. Although the num-
ber of six lymph nodes deriving by CRT algorithm from
our study was different from their minimum requirement
of twelve lymph nodes, this might highlight us that harvest
enough lymph nodes was an important prognosticator for
patients with stage II disease. Several authors suggested
that understaging might account for the underling
mechanism which explained why inadequate lymph node
yield would lead to decreased patients’ survival [26,27].
Another unexpected finding in this survival tree model
was radiotherapy. Adjuvant therapy (chemotherapy and
radiotherapy) had been advocated for certain group of
patients with colorectal cancer by several authors as alter-
natives to improve patient’s outcome [28]. While che-
motherapy could predict patients’ long-term survival in
the model, radiotherapy failed to show its importance in
this respect. The small volume of patients treated with
radiotherapy and the default setting of RPA algorithm
might somewhat explain why radiotherapy didn’t enter in
this model.
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to evaluate the consequences of patients underwent cer-
tain treatment procedures or interventions, including
overall survival, progression-free survival and disease-
specific survival [5]. Perhaps one may question why we
used cancer-specific survival as the outcome determinant
of the model building of RPA in the analysis. Overall sur-
v i v a lm i g h tb et h em o s tf r e q u e n tu s e df o r mo fs u r v i v a l
for its information easily collected. But overall survival
focused on patients’ survival during a certain period of
time regardless of patients’ reasons of death being can-
cer-related condition or not, which probably not truth-
fully reflect the consequences or outcomes of an
intervention given to a specific disease such as cancer.
For patients with cancer, especially colorectal cancer
(geriatric patients were not uncommon), the cause of
mortality might not actually related to colorectal cancer
or liver metastasis. Causes of death other than disease-
specific cancer death in this study included accident (or
suicide), old age, other cancer, diabetes, cardiovascular
accident and asthma attack, etc. So we did think the opti-
mum candidate of outcome variable in the model build-
ing process in this study was cancer-specific survival.
This study has two contributions toward predicting out-
comes after surgical intervention of colorectal cancer.
First, we tried to apply classification and regression model
for evaluating treatments of colorectal cancer patients and
to define risk groups relating to long-term survival. To the
best our knowledge, this is the first report regarding tree-
structured survival analysis for colorectal cancer surgery
using population-based data. Second, we sought to present
outcomes in three forms (overall, progression-free and dis-
ease-specific survival) simultaneously, which had rarely
been shown in related literature.
Several limitations of this method in this study should
be mentioned. First, we did not include any molecular
marker in RPA process due to unavailability of data,
which beyond the range that our population-based data
regularly collected. Second, although we try to find out
risk group definition at national level, this was not really
a 100% nationwide database of all colorectal cancer
patients. However, we thought this database (around 60%
of all colorectal cancer annually) literally enough in
representing the daily situation what we encountered
everyday. Third, we’re not sure that the findings from
our population-based dataset could be extrapolated to
other health system where multiple factors might not be
the same. After all, the healthcare insurance system in
Taiwan is a single-payer system.
Conclusions
In conclusion, our study demonstrated the utility of
classification and regression tree in patients with color-
ectal adenocarcinoma disease treated with colorectal
resection. The risk groups defined by RPA algorithm
with regard to cancer-specific survival could also predict
5-year overall and progression-free survival. RPA could
be used as an alternative method to study prognosis of
cancer. In the future, it may require more studies in
other healthcare systems to validate the utility of RPA
in colorectal cancer care.
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